{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:05:05Z","timestamp":1788833105328,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.msard.2023.104911","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T13:59:46Z","timestamp":1690466386000},"page":"104911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Is it ethical to use teriflunomide as an active comparator in phase 3 trials?"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Ann","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2023.104911_bib0001","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2174\/1570159X14666161208151525","article-title":"From leflunomide to teriflunomide: drug development and immunosuppressive oral drugs in the treatment of multiple sclerosis","volume":"15","author":"Aly","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"March","key":"10.1016\/j.msard.2023.104911_bib0002","article-title":"Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population","volume":"59","author":"Andersen","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104911_bib0003","first-page":"e26","article-title":"Freedom to Be altruistic: allowing for risk\/knowledge ratios in decisions concerning multiple sclerosis research","volume":"5","author":"Arenson","year":"2011","journal-title":"Open Med."},{"issue":"18","key":"10.1016\/j.msard.2023.104911_bib0004","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s40265-019-01229-3","article-title":"Dimethyl fumarate: a review in relapsing-remitting MS","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"April","key":"10.1016\/j.msard.2023.104911_bib0005","article-title":"Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: cross-sectional data from the Swiss multiple sclerosis registry","volume":"60","author":"Bossart","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2023.104911_bib0006","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104911_bib0007","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1352458510382129","article-title":"A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis","volume":"17","author":"Chataway","year":"2011","journal-title":"Mult. Scler."},{"issue":"9856","key":"10.1016\/j.msard.2023.104911_bib0008","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.msard.2023.104911_bib0009","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2023.104911_bib0010","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1212\/WNL.0000000000202543","article-title":"Effect of longer-term ofatumumab treatment on disability progression and brain volume change (S16.009)","volume":"100","author":"Cohen","year":"2023","journal-title":"Neurology"},{"issue":"9856","key":"10.1016\/j.msard.2023.104911_bib0011","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"The Lancet"},{"issue":"January","key":"10.1016\/j.msard.2023.104911_bib0012","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","article-title":"Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions","volume":"5","author":"Comi","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2023.104911_bib0013","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.104911_bib0014","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104911_bib0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","article-title":"Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics","volume":"22","author":"D\u2019Agostino","year":"2003","journal-title":"Stat. Med."},{"issue":"January","key":"10.1016\/j.msard.2023.104911_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.msard.2015.10.009","article-title":"The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis","volume":"5","author":"Datt","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2023.104911_bib0017","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2023.104911_bib0018","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/1352458517695468","article-title":"The efficacy of teriflunomide in patients who received prior disease-modifying treatments: subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies","volume":"24","author":"Freedman","year":"2018","journal-title":"Mult. Scler."},{"issue":"9602","key":"10.1016\/j.msard.2023.104911_bib0019","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(07)61604-3","article-title":"Non-inferiority trials are unethical because they disregard patients\u2019 interests","volume":"370","author":"Garattini","year":"2007","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.msard.2023.104911_bib0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2023.104911_bib0021","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","article-title":"A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis","volume":"9","author":"Giovannoni","year":"2020","journal-title":"Neurol. Ther."},{"issue":"January","key":"10.1016\/j.msard.2023.104911_bib0022","article-title":"Smouldering multiple sclerosis: the \u2018Real MS\u2019","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9884","key":"10.1016\/j.msard.2023.104911_bib0023","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial","volume":"381","author":"Gold","year":"2013","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.msard.2023.104911_bib0024","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"November","key":"10.1016\/j.msard.2023.104911_bib0025","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.2147\/DDDT.S236926","article-title":"Diroximel fumarate as a novel oral immunomodulating therapy for relapsing forms of multiple sclerosis: a review on the emerging data","volume":"16","author":"Hauer","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"6","key":"10.1016\/j.msard.2023.104911_bib0026","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2023.104911_bib0027","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2023.104911_bib0028","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/bimj.200800219","article-title":"Challenges and regulatory experiences with non-inferiority trial design without placebo arm","volume":"51","author":"Hung","year":"2009","journal-title":"Biom. J."},{"issue":"5","key":"10.1016\/j.msard.2023.104911_bib0029","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.104911_bib0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2023.104911_bib0031","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40120-014-0020-y","article-title":"Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis","volume":"3","author":"Kieseier","year":"2014","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2023.104911_bib0032","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/B978-0-444-53501-6.00025-1","article-title":"The ethics of clinical research in low- and middle-income countries","volume":"118","author":"Lahey","year":"2013","journal-title":"Handb. Clin. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2023.104911_bib0033","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/WNL.0000000000007938","article-title":"Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis","volume":"93","author":"Laplaud","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2023.104911_bib0034","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1080\/10543406.2021.2021227","article-title":"Conditional borrowing external data to establish a hybrid control arm in randomized clinical trials","volume":"32","author":"Li","year":"2022","journal-title":"J. Biopharm. Stat."},{"issue":"12","key":"10.1016\/j.msard.2023.104911_bib0035","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","article-title":"Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"267","author":"Li","year":"2020","journal-title":"J. Neurol."},{"issue":"March","key":"10.1016\/j.msard.2023.104911_bib0036","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1745-6215-11-31","article-title":"Reasons for participating in randomised controlled trials: conditional altruism and considerations for self","volume":"11","author":"McCann","year":"2010","journal-title":"Trials"},{"issue":"July","key":"10.1016\/j.msard.2023.104911_bib0037","doi-asserted-by":"crossref","first-page":"m2215","DOI":"10.1136\/bmj.m2215","article-title":"Non-adherence in non-inferiority trials: pitfalls and recommendations","volume":"370","author":"Mo","year":"2020","journal-title":"BMJ"},{"issue":"March","key":"10.1016\/j.msard.2023.104911_bib0038","article-title":"Effects of dimethyl fumarate on brain atrophy in relapsing-remitting multiple sclerosis: pooled analysis phase 3 DEFINE and CONFIRM studies","volume":"13","author":"Nakamura","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2023.104911_bib0039","series-title":"First Generic Versions of Aubagio\u00ae (teriflunomide) Now Available","year":"2023"},{"issue":"14","key":"10.1016\/j.msard.2023.104911_bib0040","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"13 Pt 2","key":"10.1016\/j.msard.2023.104911_bib0041","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000306410.84794.4d","article-title":"Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment","volume":"70","author":"Polman","year":"2008","journal-title":"Neurology"},{"issue":"May","key":"10.1016\/j.msard.2023.104911_bib0042","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1745-6215-12-106","article-title":"Through the looking glass: understanding non-Inferiority","volume":"12","author":"Schumi","year":"2011","journal-title":"Trials"},{"issue":"May","key":"10.1016\/j.msard.2023.104911_bib0043","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2016.03.019","article-title":"A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics","volume":"7","author":"Solomon","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2023.104911_bib0044","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1177\/1352458519855722","article-title":"Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide","volume":"26","author":"Sprenger","year":"2020","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.msard.2023.104911_bib0045","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1177\/13524585221089534","article-title":"Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: post hoc analysis of the TEMSO core and extension studies","volume":"28","author":"Sprenger","year":"2022","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2023.104911_bib0046","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2023.104911_bib0047","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/1740774511414444","article-title":"Altruism among participants in cancer clinical trials","volume":"8","author":"Truong","year":"2011","journal-title":"Clin. Trials"},{"issue":"3","key":"10.1016\/j.msard.2023.104911_bib0048","article-title":"Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate","volume":"2008","author":"Vist","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"November","key":"10.1016\/j.msard.2023.104911_bib0049","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocn.2016.02.041","article-title":"The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: a meta-analysis of randomized controlled trials","volume":"33","author":"Xu","year":"2016","journal-title":"J. Clin. Neurosci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:12:09Z","timestamp":1761901929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823004121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":49,"alternative-id":["S2211034823004121"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104911","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is it ethical to use teriflunomide as an active comparator in phase 3 trials?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104911"}}